Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 10

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 10
---
110, which is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma, is a liquid formulation of the histone deacetylase, panobinostat. Our proprietary formulation enables delivery of the product via convection-enhanced delivery at potentially chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and avoiding systemic toxicity. We have recruited the first cohort of patients in an ongoing Phase 1 study of MTX110 in recurrent glioblastoma, or rGBM. We have completed and announced the results of two Phase 1 studies in DMG. There is an ongoing Phase 1 investigator-initiated trial in medulloblastoma.

Our clinical assets are supported by three proprietary drug delivery technologies focused on improving bio-delivery and bio-distribution of drugs through either sustained delivery (Q-Sphera TM), direct delivery (MidaSolve TM), or targeted delivery (MidaCore TM):

| · | Our Q-Sphera platform: Our disruptive polymer microsphere microtechnology                                                                
 is used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. |

| · | Our MidaSolve platform: Our innovative oligosaccharide nanotechnology                                         
 is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors. |

| · | MidaCore platform: Our gold nanoparticle nanotechnology is used                                     
 for targeting sites of disease by using either chemotherapeutic agents or immunotherapeutic agents. |

We are currently focused on our clinical stage
assets and there are no active research and development programs based on our drug delivery technologies.

Recent Developments

The Committed Equity Financing

On January 17, 2025, we entered into the Purchase Agreement withthe Selling Shareholder, pursuant to which we, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, have the right, but not the obligation, to sell tothe Selling Shareholder, andthe Selling Shareholder is obligated to purchase, up to $35.0 million of newly issued Depositary Shares. As consideration for the Seller Shareholder’s execution and delivery of the Purchase Agreement, we have agreed to pay to the Selling Shareholder a fee of $875,000 in cash, or the Commitment Fee, as described further herein.

| 4 |